UTHR — UNITED THERAPEUTICS Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1082554 ·
Last close
$541.89
Market Cap
$23.24B
52W High
$609.35
52W Low
$409.07
ADV30
742,486
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 783,300,000 683,800,000 330,800,000 333,000,000 7,220,100,000 1,803,200,000 819,800,000
Mar 2026 781,500,000 648,100,000 325,800,000 274,900,000 6,714,200,000 1,279,700,000 813,100,000
Dec 2025 790,200,000 686,800,000 357,500,000 364,300,000 7,880,000,000 1,557,100,000 783,800,000
Sep 2025 799,500,000 698,600,000 389,300,000 338,700,000 7,351,100,000 1,340,100,000 760,900,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$1,685,200,000
Investing CF
$744,500,000
Financing CF
$-2,219,600,000
CapEx
$-597,700,000
Dividends Paid
—
Buybacks
$-2,554,900,000
EPS Diluted TTM
$27.95
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$9,164,800,000
Inventory
$193,800,000
Receivables
$310,300,000
ST Investments
$859,100,000
EBIT TTM
$1,585,000,000
Pretax Income TTM
$1,573,000,000
Interest Exp TTM
$12,000,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,154,500,096
EBITDA
$1,496,199,936
Free Cash Flow
$557,137,472
Enterprise Value
$18,659,092,480
Total Cash
$2,662,299,904
Total Debt
$0
Shares Out
42,890,692
Trailing EPS
$27.89
Book Value
$149.97
ROE
19.3%
ROA
11.6%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,182,700,000 1,517,200,000 1,334,700,000 7,880,000,000 783,800,000 7,096,200,000 1,561,200,000
Dec 2024 2,877,400,000 1,448,100,000 1,195,100,000 7,364,000,000 920,000,000 6,444,000,000 1,327,100,000
Dec 2023 2,327,500,000 1,184,900,000 984,800,000 7,167,000,000 1,182,200,000 5,984,800,000 978,000,000
Dec 2022 1,936,300,000 979,700,000 727,300,000 6,044,500,000 1,247,800,000 4,796,700,000 802,500,000

TTM Snapshot

Revenues TTM
$2,668,700,000
NetIncome TTM
$1,138,200,000
OpCashFlow TTM
$0
Assets (Latest)
$7,880,000,000
Forward EPS
$30.03

Max Pain — expiry 2026-10-16

max pain strike: $370.00 · spot: $541.89 · call oi: 8,327 · put oi: 0
Expected Move to 2026-10-16: ±$33.71 (6.22%) — implied range $508.18 – $575.60 · ATM straddle on $540.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GMAB GENMAB A/S $21.94B $35.67 —
GNMSF GENMAB A/S $21.83B $355.00 —
INSM INSMED Inc $24.93B $114.14 —
RPRX Royalty Pharma plc $25.99B $58.36 —
ROIV Roivant Sciences Ltd. $26.42B $36.57 —

News headlines (Yahoo Finance, 1h cache)

1 Mid-Cap Stock to Research Further and 2 That Underwhelm
2026-10-01 09:09 · Yahoo
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent
2026-10-01 01:41 · Yahoo
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
2026-09-30 23:33 · Yahoo
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
2026-09-30 23:09 · Yahoo
Sector Update: Healthcare Stocks Fall Late Afternoon
2026-09-30 20:00 · Yahoo
LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims
2026-09-30 19:46 · Yahoo
Liquidia shares crater after court rules for United Therapeutics
2026-09-30 18:23 · Yahoo
United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts
2026-09-29 01:44 · Yahoo
What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders
2026-09-27 19:10 · Yahoo
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
2026-09-25 10:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.